OCUP insider transaction filings
Ocuphire Pharma, Inc. — 23 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2024-06-13. Screen OCUP transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for OCUP between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Ocuphire Pharma, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2024-06-13 | 4 | Rodgers Richard J — Director | Grant/award (A): 41,143 @ $0 · Grant/award (A): 35,181 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Pepose Jay — Director | Grant/award (A): 41,143 @ $0 · Grant/award (A): 35,181 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | MANUSO JAMES S J — Director | Grant/award (A): 41,143 @ $0 · Grant/award (A): 35,181 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Gallagher Cam — Director | Grant/award (A): 41,143 @ $0 · Grant/award (A): 35,181 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Benton Susan — Director | Grant/award (A): 41,143 @ $0 · Grant/award (A): 35,181 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | Ainsworth Sean — Director | Grant/award (A): 41,143 @ $0 · Grant/award (A): 35,181 (derivative) @ $0 | EDGAR |
| 2024-05-24 | 4 | Jayagopal Ashwath — Chief Scientific & Dev. Ofc. | Purchase (P): 3,500 @ $1.76 | EDGAR |
| 2024-05-21 | 4 | Magrath George — Chief Executive Officer | Purchase (P): 5,000 @ $1.75 | EDGAR |
| 2024-04-15 | 4 | Pepose Jay — Director | Grant/award (A): 32,000 @ $0 · Grant/award (A): 48,000 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | Jhaveri Nirav S. — Chief Financial Officer | Purchase (P): 10,000 @ $2.10 | EDGAR |
| 2024-03-25 | 4 | SCHACHLE JOSEPH K — Chief Operating Officer | Purchase (P): 2,000 @ $2.05 | EDGAR |
| 2024-03-20 | 4 | Magrath George — Chief Executive Officer | Purchase (P): 25,000 @ $1.96 | EDGAR |
| 2024-02-14 | 4 | Jhaveri Nirav S. — Chief Financial Officer | Grant/award (A): 140,000 @ $0 · Grant/award (A): 210,000 (derivative) @ $0 | EDGAR |
| 2024-02-14 | 4 | Jayagopal Ashwath — Chief Scientific & Dev. Ofc. | Grant/award (A): 75,000 @ $0 · Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | Hoffmann Bernhard — SVP of Corp. Dev. | Grant/award (A): 20,000 @ $0 · Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-01-22 | 4 | Zaremba Rabourn Amy — SVP of Finance | Grant/award (A): 40,000 @ $0 · Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-01-12 | 4 | Zaremba Rabourn Amy — SVP of Finance | Tax withholding (F): 3,950 @ $3.27 | EDGAR |
| 2024-01-12 | 4 | Patel Ronil A. — Chief Business Officer | Tax withholding (F): 1,282 @ $3.27 | EDGAR |
| 2024-01-12 | 4 | Hoffmann Bernhard — SVP of Corp. Dev. | Tax withholding (F): 4,031 @ $3.27 | EDGAR |
| 2024-01-03 | 4 | Rodgers Richard J — Director | Grant/award (A): 24,762 | EDGAR |
| 2024-01-03 | 4 | Benton Susan — Director | Grant/award (A): 19,418 | EDGAR |
| 2024-01-03 | 4 | Pepose Jay — Director | Grant/award (A): 14,964 | EDGAR |
| 2024-01-03 | 4 | MANUSO JAMES S J — Director | Grant/award (A): 22,090 | EDGAR |
Recent 8-K events — Ocuphire Pharma, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-09 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-24 | 8-K | 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | EDGAR |
| 2026-04-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-07 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-07 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=OCUP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →